{"id":"once-daily-tacrolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12 and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of IL-2 and other cytokines essential for T-cell proliferation and immune response. The once-daily formulation represents an extended-release version designed to improve dosing convenience and potentially reduce peak-trough fluctuations compared to immediate-release tacrolimus.","oneSentence":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:19.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune conditions (off-label use)"}]},"trialDetails":[{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT05707377","phase":"PHASE2, PHASE3","title":"A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-04-17","conditions":"Primary Membranous Nephropathy","enrollment":178},{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT05490511","phase":"PHASE1","title":"Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus","status":"COMPLETED","sponsor":"Indiana University","startDate":"2022-10-31","conditions":"CBD, Transplant Complication, Kidney Disease, Chronic","enrollment":57},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT07104799","phase":"PHASE1","title":"Momelotinib During and After HCT in Myelofibrosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-01","conditions":"Myelofibrosis, Hematopoietic Cell Transplantation (HCT)","enrollment":28},{"nctId":"NCT07083830","phase":"PHASE1","title":"ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-30","conditions":"Kidney Transplant Failure and Rejection, Kidney Transplant; Complications","enrollment":24},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT07302776","phase":"PHASE1","title":"TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-02","conditions":"GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML)","enrollment":50},{"nctId":"NCT03979365","phase":"PHASE4","title":"Envarsus XR Compared to Immediate Release Tacrolimus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-18","conditions":"Kidney Transplant Recipients","enrollment":261},{"nctId":"NCT06126380","phase":"PHASE2","title":"Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Eledon Pharmaceuticals","startDate":"2023-10-25","conditions":"Kidney Transplant Rejection","enrollment":132},{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT02882828","phase":"PHASE4","title":"PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2016-10","conditions":"Allograft","enrollment":134},{"nctId":"NCT01885689","phase":"PHASE2","title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-02-10","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission","enrollment":72},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03670966","phase":"PHASE1, PHASE2","title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission","enrollment":30},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm","enrollment":15},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":"Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":68},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT03373227","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2017-12-04","conditions":"Heart Transplant Rejection, Graft Failure, Compliance, Patient","enrollment":50},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT05242315","phase":"PHASE4","title":"Extended-Release Tacrolimus Following Liver Transplantation","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-05-15","conditions":"Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction","enrollment":94},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT00544115","phase":"PHASE2","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2001-10-16","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":260},{"nctId":"NCT06960824","phase":"","title":"Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Chiesi SAS","startDate":"2025-05","conditions":"Chronic Renal Disease","enrollment":165},{"nctId":"NCT01532635","phase":"PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-03","conditions":"Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00429143","phase":"PHASE1, PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Hematologic Malignancies","enrollment":27},{"nctId":"NCT03769298","phase":"PHASE2, PHASE3","title":"CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2019-02-27","conditions":"Kidney Pancreas Transplantation","enrollment":20},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT03689075","phase":"PHASE4","title":"Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation","status":"TERMINATED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2018-11-01","conditions":"Kidney Transplant Failure, Allosensitization, Immunosuppression","enrollment":35},{"nctId":"NCT04720326","phase":"PHASE4","title":"Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Geissler","startDate":"2020-12-23","conditions":"Prophylaxis Against Liver Transplant Rejection","enrollment":268},{"nctId":"NCT03823768","phase":"PHASE4","title":"Envarsus Neurotoxicity Burden in Liver Transplant Patients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2020-01-31","conditions":"Neurotoxicity, Liver Transplant; Complications","enrollment":30},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT06867042","phase":"PHASE2","title":"Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment","status":"NOT_YET_RECRUITING","sponsor":"Jina Pharmaceuticals Inc.","startDate":"2025-04","conditions":"Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate","enrollment":150},{"nctId":"NCT04838288","phase":"PHASE4","title":"Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-06-22","conditions":"Renal Transplant","enrollment":60},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":"Kidney Transplant; Complications","enrollment":51},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT02723591","phase":"PHASE4","title":"To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-09-09","conditions":"Kidney Transplantation","enrollment":599},{"nctId":"NCT06183892","phase":"NA","title":"Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-04","conditions":"Liver Transplant","enrollment":80},{"nctId":"NCT05655273","phase":"PHASE4","title":"Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"University Health Network, Toronto","startDate":"2024-01-01","conditions":"Liver Transplant Rejection, Immune System Suppression","enrollment":40},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT02147938","phase":"","title":"A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-07-17","conditions":"Renal Transplantation","enrollment":578},{"nctId":"NCT02268201","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2013-07-23","conditions":"Kidney Transplant Recipients","enrollment":17},{"nctId":"NCT03644485","phase":"PHASE4","title":"Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-10-21","conditions":"Kidney Transplant","enrollment":284},{"nctId":"NCT01882322","phase":"PHASE4","title":"A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2013-01-30","conditions":"de Novo Liver Transplant Subjects","enrollment":36},{"nctId":"NCT03623217","phase":"","title":"Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-02-24","conditions":"Kidney Transplantation","enrollment":56},{"nctId":"NCT02143479","phase":"","title":"A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-06-18","conditions":"Liver Transplantation","enrollment":398},{"nctId":"NCT04711291","phase":"NA","title":"Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Medication Adherence, Renal Transplant","enrollment":""},{"nctId":"NCT03511560","phase":"PHASE4","title":"Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-07-26","conditions":"Renal Transplant Rejection, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT06268769","phase":"PHASE4","title":"Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs","status":"RECRUITING","sponsor":"Edward Geissler","startDate":"2024-03-09","conditions":"Immunosuppression","enrollment":300},{"nctId":"NCT02426502","phase":"NA","title":"Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2016-04","conditions":"End-Stage Renal Disease","enrollment":76},{"nctId":"NCT05807932","phase":"PHASE1, PHASE2","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2023-06-26","conditions":"Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":38},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT06342505","phase":"","title":"Tacrolimus in CD3+ T Lymphocytes","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-05-30","conditions":"Immunosuppression","enrollment":28},{"nctId":"NCT03760263","phase":"PHASE4","title":"Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus","status":"COMPLETED","sponsor":"Sentara Norfolk General Hospital","startDate":"2020-01-16","conditions":"Transplant;Failure,Kidney","enrollment":46},{"nctId":"NCT02663622","phase":"PHASE2","title":"Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)","status":"COMPLETED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2016-09-19","conditions":"Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia","enrollment":44},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":"Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma","enrollment":""},{"nctId":"NCT05089604","phase":"PHASE4","title":"Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-01-09","conditions":"Liver Transplantation, Immunosuppression, Neurotoxicity","enrollment":124},{"nctId":"NCT04496401","phase":"PHASE4","title":"PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2020-09-28","conditions":"Kidney Transplantation, Pancreas Transplantation, Diabetes","enrollment":25},{"nctId":"NCT06147375","phase":"NA","title":"Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Wei Gao","startDate":"2023-12-01","conditions":"Immune Tolerance, Immunosuppression, Liver Transplant; Complications","enrollment":47},{"nctId":"NCT02837978","phase":"PHASE4","title":"The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment","status":"COMPLETED","sponsor":"Qiang Shu","startDate":"2015-01","conditions":"Arthritis, Rheumatoid","enrollment":150},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT06057545","phase":"PHASE3","title":"Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2023-04-25","conditions":"Pediatric Kidney Disease","enrollment":30},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT04002115","phase":"PHASE2","title":"Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-06-03","conditions":"Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT03762473","phase":"PHASE2","title":"Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-05-09","conditions":"Renal Transplant Infection","enrollment":89},{"nctId":"NCT03713645","phase":"PHASE4","title":"Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Temple University","startDate":"2018-11-12","conditions":"Kidney Transplant","enrollment":36},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT03699631","phase":"PHASE2","title":"PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-11-06","conditions":"Hematologic Malignancy","enrollment":29},{"nctId":"NCT03289650","phase":"PHASE3","title":"Extended Release Tacrolimus vs. Twice-Daily Tacrolimus","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2017-09-05","conditions":"End Stage Renal Disease, Rejection of Renal Transplant","enrollment":29},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT03438773","phase":"PHASE1","title":"Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"California Institute of Renal Research","startDate":"2018-07-11","conditions":"Kidney Transplant; Complications, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT03266393","phase":"PHASE4","title":"Envarsus XR® in Adolescent Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2019-01-15","conditions":"Kidney Transplantation, Renal Transplantation, Grafting, Kidney","enrollment":28},{"nctId":"NCT04095858","phase":"PHASE3","title":"Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)","status":"TERMINATED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2021-01-05","conditions":"Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT01028716","phase":"PHASE2","title":"Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-05-19","conditions":"Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission","enrollment":46},{"nctId":"NCT04440371","phase":"NA","title":"Phototherapy Combination With Topicals in Vitiligo","status":"UNKNOWN","sponsor":"Jordan University of Science and Technology","startDate":"2020-06-21","conditions":"Vitiligo, Generalized","enrollment":40},{"nctId":"NCT04532710","phase":"PHASE2","title":"Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Marinomed Biotech AG","startDate":"2020-08-04","conditions":"Allergic Conjunctivitis, Allergic Rhinitis","enrollment":64},{"nctId":"NCT04431219","phase":"PHASE1, PHASE2","title":"First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients","status":"COMPLETED","sponsor":"Xenothera SAS","startDate":"2019-11-26","conditions":"Kidney Transplant","enrollment":10},{"nctId":"NCT03672110","phase":"PHASE3","title":"Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2014-09","conditions":"Renal Failure, Renal Insufficiency, Renal Disease","enrollment":400},{"nctId":"NCT01773395","phase":"PHASE2","title":"GVAX vs. Placebo for MDS/AML After Allo HSCT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01-08","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":123},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":151,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advagraf®"],"phase":"marketed","status":"active","brandName":"Once Daily Tacrolimus","genericName":"Once Daily Tacrolimus","companyName":"University of Saskatchewan","companyId":"university-of-saskatchewan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prophylaxis (kidney, heart, liver), Atopic dermatitis, Autoimmune conditions (off-label use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}